Comparison of newer antiarrhythmic agents.
In the past decade a number of new antiarrhythmic drugs ahve been introduced. They have been extensively used in the acute phase of myocardial infarction. Few, if any, long-term comparative trials of these newer agents have been reported. Most of these newer agents have been shown to be able to reduce the frequency of ventricular arrhythmias but not the mortality rate. Beta blockers and some antiplatelet adhesive drugs, however, have reduced the mortality rate following myocardial infarction. There is a need for long-term properly stratified trials of these effective agents.
D000319:Adrenergic beta-Antagonists / Q000494:pharmacology; D000638:Amiodarone / Q000494:pharmacology; D000813:Anilides / Q000494:pharmacology; D000889:Anti-Arrhythmia Agents; D004206:Disopyramide / Q000494:pharmacology; D006801:Humans; D008801:Mexiletine / Q000494:pharmacology; D016677:Tocainide; D014700:Verapamil / Q000494:pharmacology
D000319:Adrenergic beta-Antagonists; D000813:Anilides; D000889:Anti-Arrhythmia Agents; D008801:Mexiletine; D016677:Tocainide; D014700:Verapamil; D004206:Disopyramide; D000638:Amiodarone